Combined Model of Frameshift Mutations and Tumor Mutation Burden in Predicting Preliminary Response to Immune Checkpoint Inhibitors in NSCLC

Zhou, Huaqiang; Liu, Jiaqing; Zhang, Yaxiong; Fang, Wenfeng; Zhang, Li

doi:10.1016/j.jtho.2019.06.031

Cited by 1 publication

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…observed in patients without PD-L1 expression [44,45]. Tumor mutational burden is an index estimating the number of mutations carried out by cancer cells [46][47][48][49][50] and has been proposed as a potential predictive response factor [46][47][48][49][50]. The increased tumor mutational burden leads to the synthesis and secretion of an increased amount of neoantigens stimulating immune-response against cancer [46][47][48][49][50].…”

Section: Ongoing Studies With Immune-checkpoint Inhibitors and Possib...mentioning

confidence: 99%

“…Tumor mutational burden is an index estimating the number of mutations carried out by cancer cells [46][47][48][49][50] and has been proposed as a potential predictive response factor [46][47][48][49][50]. The increased tumor mutational burden leads to the synthesis and secretion of an increased amount of neoantigens stimulating immune-response against cancer [46][47][48][49][50]. Nonetheless, the mutational load may also increase after exposure to agents promoting DNA damage, including alkylating antitumor agents such as temozolomide [51][52][53][54][55].…”

Section: Ongoing Studies With Immune-checkpoint Inhibitors and Possib...mentioning

confidence: 99%

“…We still do not have a reliable predictive response factor to ICIs [44–50]. PD-L1 expression is surely correlated to clinical responses after ICIs administration even if this correlation is not absolute as responses can also be observed in patients without PD-L1 expression [44,45].…”

Section: Ongoing Studies With Immune-checkpoint Inhibitors and Possib...mentioning

confidence: 99%

“…PD-L1 expression is surely correlated to clinical responses after ICIs administration even if this correlation is not absolute as responses can also be observed in patients without PD-L1 expression [44,45]. Tumor mutational burden is an index estimating the number of mutations carried out by cancer cells [46–50] and has been proposed as a potential predictive response factor [46–50]. The increased tumor mutational burden leads to the synthesis and secretion of an increased amount of neoantigens stimulating immune-response against cancer [46–50].…”

Section: Ongoing Studies With Immune-checkpoint Inhibitors and Possib...mentioning

confidence: 99%

See 3 more Smart Citations

Immune-checkpoint inhibitors in pituitary malignancies

et al. 2021

View full text Add to dashboard Cite

To date, there are no standardized systemic treatment options for patients with metastatic pituitary carcinoma progressed to chemo and radiation therapy. Immunecheckpoint inhibitors (ICIs) have been successfully assessed in other solid malignancies and could be a concrete hope for these patients. We performed a critical review of the literature aimed to evaluate studies assessing ICIs in pituitary malignancies. We also conducted research about published translational data assessing immune-contexture in these malignancies. Some preliminary reports reported a successful administration of pembrolizumab or the combination between nivolumab and ipilimumab in patients with metastatic ACTH-secreting pituitary carcinomas. Translational data suggest that adenomas secreting growth hormone and ACTH have a suppressed immunemicroenvironment, which could be more likely to benefit from ICIs. Immune-checkpoint inhibitors can be an effective treatment in patients with pituitary carcinoma and maybe also recurrent adenoma. Tumors secreting growth hormone and ACTH are more likely to benefit from ICIs due to a different immune-microenvironment. Anti-Cancer Drugs 33: e28-e35

show abstract

Section: Ongoing Studies With Immune-checkpoint Inhibitors and Possib...mentioning

confidence: 99%

Section: Ongoing Studies With Immune-checkpoint Inhibitors and Possib...mentioning

confidence: 99%

Section: Ongoing Studies With Immune-checkpoint Inhibitors and Possib...mentioning

confidence: 99%

Section: Ongoing Studies With Immune-checkpoint Inhibitors and Possib...mentioning

confidence: 99%

See 2 more Smart Citations

Immune-checkpoint inhibitors in pituitary malignancies

et al. 2021

View full text Add to dashboard Cite

show abstract

Combined Model of Frameshift Mutations and Tumor Mutation Burden in Predicting Preliminary Response to Immune Checkpoint Inhibitors in NSCLC

Cited by 1 publication

References 3 publications

Immune-checkpoint inhibitors in pituitary malignancies

Immune-checkpoint inhibitors in pituitary malignancies

Contact Info

Product

Resources

About